Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date
Pietro Enea Lazzerini,1 Pier Leopoldo Capecchi,1 Giacomo Maria Guidelli,1 Enrico Selvi,1 Maurizio Acampa,2 Franco Laghi-Pasini1 1Department of Medical Sciences, Surgery and Neurosciences, University of Siena, 2Stroke Unit, University Hospital of Siena, Siena, Italy Abstract: Rheumatoid ar...
Main Authors: | Lazzerini PE, Capecchi PL, Guidelli GM, Selvi E, Acampa M, Laghi-Pasini F |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-09-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/spotlight-on-sirukumab-for-the-treatment-of-rheumatoid-arthritis-the-e-peer-reviewed-article-DDDT |
Similar Items
-
Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients
by: Tsutomu Takeuchi, et al.
Published: (2018-03-01) -
A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis
by: Wolfgang A. Schmidt, et al.
Published: (2020-08-01) -
Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
by: Crotti C, et al.
Published: (2017-01-01) -
Primary pathologic role of interleukin-6 in rheumatoid arthritis
by: G.L. Bajocchi, et al.
Published: (2013-05-01) -
Rheumatoid arthritis and bacterial infections
by: N L Prokopjeva, et al.
Published: (2008-02-01)